Mineral Forms · Mineral
Chromium Propionate
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Chromium propionate is a trivalent chromium [Cr(III)] salt formed with propionic acid, proposed to support glucose metabolism by potentiating insulin signaling through chromodulin (low-molecular-weight chromium-binding substance). Unlike better-studied forms such as chromium picolinate, chromium propionate lacks dedicated human clinical trials, making its efficacy and optimal dosage largely extrapolated from general Cr(III) research.
Chromium propionate is a synthetic organometallic compound consisting of trivalent chromium (Cr(III)) bound to propionate ligands, with the molecular formula Cr(CH₃CH₂COO)₃ and molecular weight of 271.15 g/mol. It appears as a green powder that is easily soluble in water and is formed through chemical synthesis rather than extraction from natural sources.
No human clinical trials, randomized controlled trials, or meta-analyses specifically on chromium propionate were found in the research. The compound appears to be primarily used in animal nutrition applications, with human research completely absent from available sources.
No clinically studied dosage ranges for chromium propionate in humans are documented. Commercial animal products contain 0.4% chromium from propionate, but no human dosing data or standardization exists. Consult a healthcare provider before starting any new supplement.
Chromium Propionate is an organochromium coordination compound consisting of trivalent chromium [Cr(III)] chelated with propionate ligands (CH3CH2COO-). As a pure mineral supplement ingredient, it contains no macronutrients (zero protein, fat, or carbohydrates), no dietary fiber, and no caloric value. The primary active constituent is elemental chromium in the +3 oxidation state, typically delivering 12-15% elemental chromium by molecular weight based on the Cr(III)-propionate complex structure. At a representative supplemental dose of 200 mcg chromium equivalent, the compound provides chromium at approximately 10-25% of the Adequate Intake (AI) for chromium (25-35 mcg/day for adults), though typical supplemental doses far exceed dietary AI levels. No vitamins, secondary minerals, or fiber are present. Bioavailability: Cr(III) in organic chelate forms such as propionate is theorized to have superior intestinal absorption compared to inorganic chromium salts (e.g., chromium chloride, ~0.4-2% absorption), with organic forms potentially reaching 2-5% absorption efficiency, though propionate-specific human bioavailability data is absent. Absorption occurs primarily in the small intestine via passive diffusion and possibly carrier-mediated transport. The propionate ligand itself (a short-chain fatty acid, C3) contributes negligible nutritional significance at supplemental doses. No co-factors, phytochemicals, or bioactive secondary compounds are present beyond the Cr(III) coordination complex itself.
Chromium propionate dissociates in vivo to release Cr(III) ions, which are incorporated into chromodulin (also called low-molecular-weight chromium-binding substance, LMWCr), a oligopeptide that amplifies insulin receptor tyrosine kinase activity upon insulin binding. This chromodulin-mediated signal amplification enhances downstream phosphorylation of insulin receptor substrate-1 (IRS-1), facilitating GLUT4 translocation to cell membranes and increasing cellular glucose uptake. The propionate ligand may influence bioavailability and intestinal absorption kinetics compared to other Cr(III) chelates, though this pharmacokinetic distinction has not been quantified in peer-reviewed human studies.
No published randomized controlled trials have specifically examined chromium propionate in human subjects as of 2024, placing it among the least-evidenced chromium salt forms. Evidence for benefit is extrapolated from research on chromium picolinate and chromium nicotinate, where meta-analyses of 15–20 small trials (typically n=20–50) showed modest reductions in fasting blood glucose (approximately 0.5–1.0 mmol/L) and HbA1c in type 2 diabetic populations. Animal studies using Cr(III) propionate in cattle and swine have reported improved insulin sensitivity and altered lipid profiles, but interspecies extrapolation to humans is unreliable. Overall, the evidence base for chromium propionate specifically is considered preliminary and insufficient to support definitive clinical recommendations.
Chromium propionate is presumed to share the general safety profile of other Cr(III) compounds, which are considered low-toxicity at supplemental doses typically ranging from 200–1000 mcg elemental chromium per day; however, no formal toxicology studies specific to the propionate salt in humans have been published. High-dose Cr(III) supplementation has been associated in rare case reports with renal and hepatic dysfunction, and caution is warranted in individuals with pre-existing kidney or liver impairment. Chromium may potentiate the hypoglycemic effects of insulin, metformin, and sulfonylureas, requiring blood glucose monitoring if co-administered. Safety during pregnancy and lactation has not been established for this specific form, and use should be avoided without physician supervision.
